ELSEVIER

Contraception
1998;57:421–422

Author Index
Volume 57
January–June 1998

Affandi, Biran, 1
Alfthan, Henrik, 257
Andersson, Kerstin, 251
Andreas, Jens-Otto, 103
Ansari, A.S., 271
Anzaldua, Santiago Rene, 349

Bahamondes, Luis, 413
Balasinor, N., 261
Blumenthal, Paul D., 99, 1S
Brache, Vivian, 1
Brenner, Paul F., 287
Bruce, J. Malcolm, 111
Bruppacher, Rudolf, 29
Bühler, K., 385
Buytaert, P., 45

Cabezas, E., 83, 329
Camacho-Arroyo, Ignacio, 349
Carbonell, J.L.L., 83
Carbonell Esteve, J.L., 329
Cerbón, Marco A., 349
Cetin, Ali, 393
Cetin, Meral, 393
Chang, C.L., 61
Chantler, Eric, 111
Chen, J.H., 371
Cheng, Linan, 89
Chiaffarino, Francesca, 11
Coelingh Bennink, H.J.T., 385
Collins, John, 211
Cong, J., 371
Conwit, Robin A., 99
Crook, David, 189
Crosignani, Pier Giorgio, 11
Croxatto, Horacio B., 1
Cushman, Linda, 237, 241

d'Arcangues, C., 23, 71
D'Souza, S., 261
Davidson, Andrew, 237, 241
Davie, J., 19
de Carvalho, João Ernesto, 335
de Jong-van den Berg, L.T.W., 247
de Vries, C.S., 237
Degezelle, H., 45
Diaz, Soledad, 1
Dinchuen, Petcharat, 23
Dolder, Heidi, 335
Dong, J., 371
Duncan, Bruce B., 93

Edström, Birgitte, 291
Eick, S., 381
Ellertson, Charlotte, 363

Farheen, S., 55
Farley, Timothy M.M., 61, 211
Farmer, R.D.T., 67
Faúndes, Anibal, 413
Faúndes, Daniel, 413
Fehring, Richard J., 325
Felix, Juan Carlos, 399
Fernández, C., 83
Fleming, Diana, 19
Fotherby, K., 183
Fraser, Ian S., 1

Gao, J., 371
Gao, Pei Pei, 89
García, Gustavo A., 349
Gaska, Nancy, 325
Geurts, T.B.P., 385
Gill-Sharma, M.K., 261
Ginsburg, Jean, 1
Glasier, A., 19
Godsland, Ian, 189
Goldberg, Jutta, 103
Gopalkrishnan, K., 261
Gräser, T., 381
Gu, Sujuan, 1
Guggenmoos-Holzmann, Irene, 29
Gwanmesia, Ivo L., 111

Han, Xue-jan, 405
Hannaford, Philip, 137
Heartwell, Stephen, 237, 241
Heinemann, Lothar A.J., 29
Ho, Pak Chung, 89
Holma, Pentti, 1
Howie, H., 385
Hu, J., 371
Huggins, George R., 1S

Jayaraman, S., 261
Johansson, Elof, 1
Juneja, H.S., 261

Kalmuss, Debra, 237, 241
Keshri, G., 357
Kitchlu, S., 55
Klinger, Gisela, 381
Klinger, G., 381

Koepsell, Thomas D., 361
Koetsawang, Suporn, 23
Korver, T., 385
Kreiner, Svend, 291, 303
Kumar, Y., 271

La Vecchia, Carlo, 11
Lakshmi, V., 357
Lammers, Paul, 1S
Lee, Sharon, 89
Lehtovirta, Pentti, 257
Letterie, Gerard S., 39
Lewis, Michael A., 29, 67
Lidegaard, Øjvind, 291, 303
Lindall, Kerstin, 251
Lohiya, N.K., 125, 271
Longstreth Jr., W.T., 361

MacRae, K.D., 67
Manivannan, B., 125
Mant, Jonathan, 231
Marmot, M.G., 61
Mehrotra, P.K., 55
Meirik, Olav, 1, 61, 135
Mengue, Sotero S., 93
Miao, L., 371
Milsom, Ian, 251
Mishell Jr, Daniel R., 1
Mishra, P.K., 125
Montanari, Tatiana, 335
Moore, Claudia, 381
Moyer, Dean L., 399

Nash, Harold A., 1

Odlind, Viveca, 251
Oettel, M., 381

Padwal, V., 261
Painter, Rosemary, 231
Parazzini, Fabio, 11
Parte, P., 261
Patrasupapong, Nuanchan, 23
Petitti, Diana B., 143, 361
Petta, Carlos Alberto, 413
Pfister, W., 381
Phillips, David M., 341
Piaggio, G., 23
Pinol, A., 23
Piya-Anant, Manee, 23
Poulter, N.R., 61, 315
Psaty, Bruce M., 361

© 1998 Elsevier Science Inc. All rights reserved.
655 Avenue of the Americas, New York, NY 10010

ISSN 0010-7824/98/$19.00
PII S0010-7824(98)00051-1

Contraception
1998;57:421–422

Quesenberry, Charles P., 143, 361

Raghunathan, Trivellore E., 361
Ramaekers, P., 45
Reinprayoon, Damrong, 417
Renier, M.A., 45
Ricci, Elena, 11
Rodríguez, Germán, 363
Rulin, Marvin, 237, 241
Ryde-Blomqvist, Elsa, 251

Sánchez, C., 83, 329
Sang, Guo-wei, 405
Schenkel, Eloir P., 93
Schlesselman, James J., 211
Schmidt, Maria Inês, 93
Schwartz, Stephen M., 361
Shao, Qing-xiang, 405
Shao, W.Q., 371
Sidney, Steve, 143
Sidney, Stephen, 361
Singh, M.M., 357
Siscovick, David S., 361
Sivin, Irving, 1
Smith, Jeffrey M., 99
Spitzer, Walter O., 29, 64
Srivastava, S., 271
Stenman, Ulf-Håkan, 257
Straetmans, D., 45
Suissa, Samy, 64

Tanda, R., 329
Taneepanichskul, Surasek, 417
Tang, Oi Shan, 89
Teng, Ching-Sung, 117, 281
Thorogood, Margaret, 29, 157
Tiitinen, Aila, 1
Todd, J.-C., 67
Transnational Group on Oral Contraceptives and the Health of Young Women, 29
Truman, Christine, 237, 241
Trussell, James, 363

United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation, 71

van den Berg, P.B., 247
Van Herck, E., 45
Vanderheyden, J., 45
Varela, L., 83, 329
Vartiainen, Juhani, 257
Velazco, A., 83, 329
Vereecken, A., 45
Vessey, Martin, 231
Vilagrasa, Xavier, 117
von Schoultz, Bo, 1

Walker, Alexander M., 169
Wang, C., 371
Weng, Li-ju, 405
Westhoff, Carolyn, 237, 241
Williams, T.J., 67
Winkler, Ulrich H., 203, 385
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception, 315
Wu, S.C., 371

Xiao, B.L., 371
Xu, Naixin, 49
Xue, Huashi, 49

Zacharopoulos, Vaneja R., 341
Zahradnick, Hans P., 103
Zhang, Chengdian, 49
Zhou, Xiao-fei, 405
Zou, M.H., 371

ELSEVIER

Contraception
1998;57:423–425

Subject Index
Volume 57
January–June 1998

Abortion,
  management with use of transvaginal sonography, 393
  methotrexate + misoprostol, 83
  mifepristone + misoprostol, 89
  misoprostol, 329
Acceptance, ethinyl estradiol + desogestrel, 8S
Amenorrhea induced by DMPA,
  treatment with Cyclofem®, 23

Belara®, ethinyl estradiol + chlormadinone acetate, 103
Benign gynecologic diseases and OC use, 11
Blood coagulation and OC, 203
Breastfeeding women,
  use of progesterone-releasing vaginal ring, 371
  use of TCu 380A, 371

Carbohydrate metabolism, effect of OC, 189
Cardiovascular disease,
  Norplant® implants and, 361
  OC use and, 211
Cardiovascular disease risks
  OC and, 137
  steroid hormonal contraceptives use, 315
Cardiovascular safety and OC, 135
Cerebral thrombosis and OC, 303
Choriocarcinoma, masked by contraceptive use, 257
Clinical and biological effects, Norplant® implants, 1
Clinical safety, ethinyl estradiol + desogestrel, 13S
Clinical trial, ethinyl estradiol + chlormadinone acetate, 103
Consensus statement, Norplant® implants, 1
Continuation rates,
  copper IUD users, 19
  Norplant® implant users, 19
Contraceptive activity, indigenous plants (rat), 357
Contraceptive developments, ethinyl estradiol + desogestrel, 1S
Contraceptive Revolution, The (book review), 287
Contraceptive use, choriocarcinoma masked, 257
Copper corrosion, effect of indomethacin, 49
Copper IUD, continuation rates, 19
Corrosion of copper, effect of indomethacin, 49
Cyclofem®,
  DMPA + estradiol cypionate, 23, 71
  pharmacokinetics of medroxyprogesterone acetate, 405

Delayed diagnosis of choriocarcinoma,
  use of contraceptive, 257
Depo-Provera® and depressive symptoms, 237
Depressive symptoms,
  Depo-Provera® and, 237
  Norplant® implants and, 241
Desogestrel
  effect on haemostasis, 6-2
  pharmacokinetics, 5S
Diffusion into semen, nonoxynol-9, 111
DMPA (depot medroxyprogesterone acetate) + estradiol cypionate, 23, 71
DMPA-induced amenorrhea treatment, use of Cyclofem®, 23
Drugs to induce menstruation, prevalence of unsuccessful use, 93

Effectiveness, Yuzpe method, 363
Efficacy, oral contraceptives, 6S
Emergency contraception, Yuzpe method, 363
Endometrium,
  effect of progesterone, 399
  effect of synthetic progestins, 399
Enzyme inhibitors and polyamine biosynthesis (mouse, hamster), 55
Epidemiological issues, safety of OC, 137
Ethinyl estradiol + chlormadinone acetate, 103
Ethinyl estradiol + desogestrel, 381, 1S
Ethinyl estradiol + dienogest, 381

Family planning services, Norplant® implants, 1
Fertile period determination, use of Lady Free Biotester®, 325
First generation OC, 29, 157, 291, 303
Fractures and OC use, 231

Gingival microbial flora, influence of hormonal contraceptives, 381
Glucose metabolism,
  effect of DMPA + estradiol cypionate, 71
  effect of norethisterone enanthate + estradiol valerate, 71
Gossypol, effect on spermatocytes (rat), 117, 281
Gynecologic disease and OC use, 11

Haemostasis,
  effect of desogestrel, 385
  effect of levonorgestrel, 385
Herpes simplex virus, effect of nonoxynol-9 on (mouse), 341
Hormonal contraceptives, influence on gingival microbial flora, 381
Hormonal profile, effect of tamoxifen (male rat), 261

© 1998 Elsevier Science Inc. All rights reserved.
655 Avenue of the Americas, New York, NY 10010

ISSN 0010-7824/98/$19.00
PII S0010-7824(98)00052-3

Contraception
1998;57:423–425

Implant contraceptive, levonorgestrel,1, 241
Implant removal complication, 99
Indigenous plants, contraceptive activity (rat), 357
Indomethacin, effect on corrosion of copper, 49
Inhibins, markers of ovarian activity, 45
Injectable contraceptive,
  DMPA, 23, 237
  DMPA + estradiol cypionate, 23, 71, 405
  norethisterone enanthate + estradiol valerate, 71
Intrauterine device (IUD),
  continuation rates, copper IUD users, 19
  perforations, 251
  position, evaluation by transvaginal sonography, 413
  TCu 380A, 371, 417

Lady Free Biotester®, determining the fertile period, 325
Levonorgestrel, effect on haemostasis, 385
Lipoprotein levels, effect of OC, 189
Liver function,
  effect of DMPA + estradiol cypionate, 71
  effect of norethisterone enanthate + estradiol valerate, 71

Male reproduction, effect of tolnidamine (rabbit), 271
Maytenus ilicifolia leaves, effect on spermatogenesis (mouse), 335
Medroxyprogesterone acetate, pharmacokinetics, 405
Menstrual induction, unsuccessful use of drugs, 93
Mesigyna®, norethisterone enanthate + estradiol valerate, 71
Metabolic interrelationships and OC, 183
Metabolism, effect of tolnidamine (male rabbit), 271
Methotrexate + misoprostol, 83
Mifepristone + misoprostol, 89
Misoprostol,
  abortion, 329
  methotrexate and, 83
  mifepristone and, 89
  prolonged use following termination of pregnancy, 89
Myocardial infarction and OC, 143

Noncontraceptive health benefits, oral contraceptives, 20S
Nonoxynol-9,
  diffusion into semen, 111
  effect on Herpes simplex infection (mouse), 341
Norethisterone, effect on reproductive tract (rabbit), 349
Norplant® implants,
  cardiovascular disease, 361
  clinical and biological effects, 1
  consensus statement, 1
  continuation rates, 19
  depressive symptoms, 241
  experience in family planning services, 1
  injury during removal, 99
  performance, 1

Oral contraceptive (OC),
  benign gynecological conditions and OC use, 11
  blood coagulation, 203
  cardiovascular risks, 211, 137
  cardiovascular safety, 135
  cerebral thrombosis, 303
  effect on carbohydrate metabolism, 189
  effect on lipoprotein levels, 189
  ethinyl estradiol + chlormadinone acetate, 103
  ethinyl estradiol + desogestrel, 381
  ethinyl estradiol + dienogest, 381
  ethinyl estradiol + norethindrone, 39
  first generation, 29, 157, 291, 303
  fractures and OC use, 231
  historical development, 1S
  metabolic interrelationships, 183
  myocardial infarction and OC use, 143
  pharmacology, 3S
  restricted to periovulatory period, 39
  second generation, 29, 61, 67, 157, 247, 291, 303
  stroke risk and OC use, 157
  third generation, 29, 61, 67, 157, 169, 247, 291, 303
  thromboembolic stroke and OC use, 29
  use after pill scare, 247
  venous thromboembolism risk and OC use, 61, 67, 169, 291
Ovarian activity, assessment by levels of inhibins, 45

Perforations with IUD, 251
Performance, Norplant® implants, 1
Perimenopausal women, use of TCu 380A, 417
Pharmacokinetics, medroxyrogesterone acetate, 405
Pill scare, changes in OC use, 247
Pill-free interval, assess ovarian activity, 45
Plants, contraceptive activity (rat), 357
Polyamine biosynthesis and enzyme inhibitors (mouse, hamster), 55
Progesterone, effect on endometrium, 399
Progesterone-releasing vaginal ring, 371

Rectal infection by Herpes simplex, effect of nonoxynol-9 (mouse), 341
Reproductive tract, effect of 5-norethisterone (rabbit), 349
Restricted OC regimen, effectiveness, 39

Safety, ethinyl estradiol + desogestrel, 13S
Second generation OC, 29, 61, 67, 157, 247, 291, 303
Semen, diffusion of nonoxynol-9, 111
Spermatocytes, effect of gossypol (rat), 117, 281
Spermatogenesis, effect of *Maytenus ilicifolia* leaves (mouse), 335

Spermatozoa, effect of styrene maleic anhydride (monkey), 125
Spontaneous abortion, management with use of transvaginal sonography, 393
Steroid hormonal contraceptives, risks of cardiovascular disease, 315
Stroke and OC, 157
Styrene maleic anhydride, effect on spermatozoa (monkey), 125
Synthetic progestins, effect on endometrium, 399

T-shaped IUD, position evaluated by transvaginal sonography, 413
Tamoxifen,
  effect on hormonal profile (male rat), 261
  effect on testis (rat), 261
TCu 380A, 371, 417
Testicular tissue, effect of gossypol (rat), 117
Testis, effect of tamoxifen (rat), 261
Third generation OC, 29, 61, 67, 157, 169, 247, 291, 303
Thromboembolic stroke and OC use, 29
Tolnidamine,
  effect on metabolism (male rabbit), 271
  effect on reproduction (male rabbit), 271
Transvaginal sonography,
  evaluation of T-shaped IUD position, 413
  management of spontaneous abortions, 393

Ulnar nerve injury, removal of Norplant® implants, 99
Uterine perforations, IUD, 251

Vas occlusion, styrene maleic anhydride (monkey), 125
Venous thromboembolism risk and OC, 61, 67, 169, 291

Yuzpe method,
  effectiveness, 363
  emergency contraception, 363